{"title":"Nasal Microbiota as a Potential Therapeutic Target for Allergic Rhinitis: An Emerging Perspective.","authors":"Bing-Yu Liang, Yi-Pin Yang, Chun-Ya Pan, Fen-Fen Li, Ping-Ting Zhou, Zi-Yue Fu, Yan-Xun Han, Qin Wang, Hai-Feng Pan, Yu-Chen Liu","doi":"10.2174/0113816128388496250812102820","DOIUrl":"https://doi.org/10.2174/0113816128388496250812102820","url":null,"abstract":"<p><p>Allergic Rhinitis (AR) represents a significant global health challenge with extensive prevalence and profound impacts, necessitating the development of novel therapeutic approaches beyond conventional symptomatic treatment. Emerging research has elucidated the crucial role of nasal microbiota dysbiosis in both the pathogenesis and progression of AR. Although the dominant microbial phyla remain largely consistent, significant changes in microbial abundance, composition, and diversity are often observed. In addition, studies have shown a correlation between changes in nasal microbiota and immune markers such as immunoglobulin E levels, suggesting that microbiota changes can reflect the severity of AR. Therefore, targeted modulation of the aberrant nasal microbiota may offer a promising therapeutic approach for this disease. However, further research is crucial for elucidating the causal relationships between specific microbial characteristics, disease severity, and potential comorbidities. This article summarizes recent studies examining the pathogenic role of nasal microbiota dysbiosis, the differential microbial composition across nasal mucosal sites, and potential therapeutic targets in AR. The ultimate goal is to develop precision medicine-based therapeutic interventions that target the underlying pathophysiological mechanisms of AR through specific modulation of dysbiotic nasal microbiota, thereby potentially preventing disease progression and reducing the risk of associated comorbidities.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Unraveling the Complexity of Polycystic Ovary Syndrome: Biomarkers for Diagnosis, Prognosis, and Treatment.","authors":"Saloni Upadhyay, Avijit Mazumder, Saumya Das","doi":"10.2174/0113816128382284250822045319","DOIUrl":"https://doi.org/10.2174/0113816128382284250822045319","url":null,"abstract":"<p><p>Polycystic ovary syndrome is distinguished by alterations in ovarian morphology, ovulatory failure, and increased androgen levels. The National Institutes of Health (NIH) defines it as ovulatory dysfunction accompanied by hyperandrogenism. Women with PCOS may have obesity, type 2 diabetes, anxiety, hypertension, insulin resistance, and pregnancy-related complications. PCOS is additionally linked with a greater chance of cardiovascular and metabolic disorders. Several factors, including LH/FSH ratio, FAI levels, and ovarian USG, should be considered when diagnosing PCOS. The Rotterdam criterion is employed to determine the condition when two of the three features are present and other etiologies are eliminated. Biomarkers have developed as a means of optimizing PCOS diagnosis and treatment results. This review has examined a number of biomarkers associated with PCOS, such as insulin, anti-Mullerian hormone, oxidative stress markers, inflammatory markers, and others. Controlling these disease-related markers may aid in lessening the symptoms of PCOS.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Flavonoids as Dual Inhibitors of MELK and LYN Kinases in Cervical Cancer: An In Silico Molecular Docking Analysis.","authors":"Khalid Zoghebi, Abdulmajeed M Jali","doi":"10.2174/0113816128387273250823102532","DOIUrl":"https://doi.org/10.2174/0113816128387273250823102532","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer (CC) is among the most prevalent cancers affecting women globally, with a substantial number of deaths reported annually. Despite advancements in treatment, the persistently high mortality rate underscores the urgent need for novel and effective therapeutic strategies.</p><p><strong>Methods: </strong>This study screened a library of 240 flavonoids against maternal embryonic leucine zipper kinase (MELK) and LYN using molecular docking methods to achieve precise calculations. These proteins play critical roles in CC progression, and their simultaneous inhibition could mark a significant step forward in multitargeted drug design.</p><p><strong>Results: </strong>Molecular docking revealed binding affinities ranging from -10.0649 to -8.14296 kcal/mol for MELK and -10.2748 to -8.5237 kcal/mol for LYN. The screening process was complemented by pharmacokinetics and interaction fingerprinting analyses, which confirmed that the flavonoids effectively bound to optimal sites, forming stable complexes through multiple interactions. Molecular dynamics simulations extended to 100 ns further validated the stability of these protein-ligand complexes.</p><p><strong>Discussion: </strong>The findings indicate that the top-ranked compounds exhibit strong binding affinities and stable interactions, highlighting their potential as multitargeted therapeutic agents against CC.</p><p><strong>Conclusion: </strong>These findings set the stage for future experimental and clinical studies to validate our results and facilitate the development of novel, flavonoid-based therapeutic strategies against cervical cancer, potentially revolutionizing the treatment landscape of this disease.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Green Tea Catechins and COVID-19: Epidemiological Trends and Therapeutic Perspectives.","authors":"Maksim Storozhuk","doi":"10.2174/0113816128412495250824132514","DOIUrl":"https://doi.org/10.2174/0113816128412495250824132514","url":null,"abstract":"<p><strong>Introduction: </strong>Pharmacological studies in vitro demonstrate the preventive and therapeutic potential of green tea and its constituent epigallocatechin-3-gallate (EGCG) in the fight against coronavirus disease 2019 (COVID-19). Previously reported correlations between per capita green tea consumption and COVID-19 morbidity/mortality suggest similar effects in vivo. Considering that some recent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) sub-variants are less influenced by EGCG, this study aimed to determine whether this affects the aforementioned correlations, focusing on comparisons between the periods before (2021) and after (2022-2024) the emergence of the Omicron variant.</p><p><strong>Methods: </strong>Correlations between per capita green tea consumption and COVID-19 morbidity/mortality were calculated using multiple regression models accounting for several confounding factors in a subset (n=84) of countries/territories worldwide with Human Development Index (HDI) above 0.55.</p><p><strong>Results: </strong>Higher per capita green tea consumption was associated with lower COVID-19 morbidity and mortality. Statistically significant correlations were observed in 2021-2024. Compared with 2021, the strength of both correlations decreased; the relative decrease in the strength of the correlation between per capita green tea consumption and COVID-19 mortality was notably less pronounced.</p><p><strong>Discussion: </strong>This differential decrease at the epidemiological level supports the idea that green tea consumption may have not only preventive but also therapeutic value regarding COVID-19. This aligns with in vitro pharmacological evidence indicating that green tea constituents target distinct molecular pathways responsible for the entry of the virus and its replication.</p><p><strong>Conclusion: </strong>While promising, these findings require further assessment in observational and interventional studies focused on potential therapeutic benefits.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Future Directions.","authors":"Marcio F Chedid, Jane Mattei","doi":"10.2174/0113816128436770250828043354","DOIUrl":"https://doi.org/10.2174/0113816128436770250828043354","url":null,"abstract":"","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shane Marie S Coronel, Cheng-Yang Hsieh, Kathlia A De Castro-Cruz, Hung-Yu Shu, Po-Wei Tsai
{"title":"Evaluation of the Antibacterial Activity of Rheum palmatum Processed by Different Methods Against Staphylococcus aureus using Integrated in vitro and in silico Approaches.","authors":"Shane Marie S Coronel, Cheng-Yang Hsieh, Kathlia A De Castro-Cruz, Hung-Yu Shu, Po-Wei Tsai","doi":"10.2174/0113816128407567250729054441","DOIUrl":"https://doi.org/10.2174/0113816128407567250729054441","url":null,"abstract":"<p><strong>Introduction: </strong>Traditional Chinese Medicine (TCM) employs various processing methods to enhance the bioactivity of herbs. Rheum palmatum (R. palmatum) is commonly processed to optimize its medicinal properties, yet its antibacterial activity under different processing techniques remains unclear. Standardizing preparation methods is essential for ensuring consistent therapeutic efficacy. This study examines how different processing methods influence the antibacterial activity of R. palmatum, contributing to the standardization of TCM preparation.</p><p><strong>Materials and methods: </strong>R. palmatum roots underwent 10 different water-based processing methods. Antibacterial activity against S. aureus was assessed using disc diffusion and broth microdilution assays. The most effective extracts were further analyzed via molecular docking to evaluate their binding interactions with bacterial virulence proteins (α-hemolysin and Catalase).</p><p><strong>Results: </strong>Disc diffusion and MIC results showed that RP-4 (high-pressure steamed with wine) exhibited the largest inhibition zone (11.67 mm) and the lowest MIC (1250 μg/mL). Compared to other tested microorganisms, selective inhibition was also observed against S. aureus. Molecular docking revealed that Rhein, a major active compound identified in the RP-4 extract, exhibited strong binding affinity to α-hemolysin and Catalase, comparable to standard antibiotics.</p><p><strong>Discussion: </strong>RP-4, processed through high-pressure steaming with wine, showed the strongest antibacterial activity based on ZOI and MIC results. Wine processing enhances the dissolution of active compounds, while high-pressure steaming reduces anthraquinone derivatives that cause digestive problems. Molecular docking also confirmed interactions between Rhein and the virulent proteins α-hemolysin and Catalase, suggesting a potential mechanism for inhibiting S. aureus.</p><p><strong>Conclusion: </strong>Processing methods significantly influence the antibacterial properties of R. palmatum. RP-4 demonstrated the strongest activity against S. aureus, making it a promising candidate for future TCM formulation and antibacterial drug development.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development of Novel Approaches for the Treatment of Cutaneous Candidiasis.","authors":"Abhay Kumar Singh, Rupa Mazumder, Anmol Dogra","doi":"10.2174/0113816128379927250807064636","DOIUrl":"https://doi.org/10.2174/0113816128379927250807064636","url":null,"abstract":"<p><p>The main culprit behind cutaneous candidiasis, a fungal infection that can lead to major dermatological and systemic health problems, is Candida albicans. Over the past 20 years, cutaneous candidiasis has become more prevalent, especially in hospitalized or immunocompromised patients. Conventional treatment methods employ antifungal drugs like azoles and polyenes, which are effective but have drawbacks because of their high recurrence rates, negative side effects, and growing antifungal resistance. This study highlights recent advancements in novel treatment techniques for cutaneous candidiasis. New antifungal medications that more precisely target specific fungal pathways, including echinocandins and triazole derivatives, are examples of emerging techniques. The most common symptoms are interdigital candidiasis, cheilitis, intertrigo, and diaper dermatitis, but they can occur elsewhere in the body. Other types of Candida may be the reason for infections that occur from person to person, even though C. Candida albicans is the most frequent culprit. The most typical signs of Candida infections are burning and tingling. Skin symptoms might vary, in any case. The two main signs of candidiasis are bright erythema and skin erosions with satellite pustules. Yeast is the main cause of cutaneous candidiasis. Candida, especially Candida albicans, is characterized by epidermal exposure of the skin, nails, interdigital space, and mucous membranes. This study discusses several species of Candida. parapsilosis, C. kefyr, C. krusei, C. glabrata, C. tropicalis, C. parapsilosis, C. guilliermondii, C. lusitaniae, and C. albicans. The primary targets of antifungal drugs are the nucleic acids, cell walls, and cell membranes of Candida species.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Recent Advances in Possible Treatment Options Including Herbal Remedies for the Management of Cholelithiasis.","authors":"Afridi Shafik Chabru, Ankita Das, Amoolya Sree, Payel Chakraborty, Surjeet Dhiman, Rimpa Karmakar, Abhinab Goswami, Tamilvanan Shunmugaperumal","doi":"10.2174/0113816128383672250805175516","DOIUrl":"https://doi.org/10.2174/0113816128383672250805175516","url":null,"abstract":"<p><p>Cholelithiasis, particularly cholesterol-bearing-stones, is one of the gastrointestinal diseases representing a substantial global health burden. The five key primary factors inducing cholesterol-bearing-stones include genetics, hepatic cholesterol hypersecretion, rapid phase transition of cholesterol, gallbladder hypomotility, and specific intestinal factors. To date, laparoscopic cholecystectomy remains the primary treatment approach for cholelithiasis patients. The various non-surgical methods, such as bile acid therapy, novel drug candidates, and herbal remedies, are detailed. Special attention is paid to the development of ursodeoxycholic acid (UDCA)-embedded formulations. Because the UDCA is a biopharmaceutical classification system class II drug, it poses the challenge of low aqueous solubility and thus, limited oral bioavailability. Additionally, promising developments in novel drug candidates (e.g., alirocumab), probiotics, stents, and herbal treatments with purported gallstone-dissolving properties are highlighted. The development of effective non-surgical treatments like various UDCA formulations and novel drug candidates is crucial. Additionally, the integration of herbal remedies into mainstream treatment protocols could offer significant benefits. Future research should focus on optimizing these therapies and exploring personalized treatment. Furthermore, emerging curative approaches such as gene-tailored therapy hold a future direction with a concrete perspective.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Medisetti Manikishore, Sunny Rathee, Abhay Singh Chauhan, Umesh K Patil
{"title":"Watermelon Rind: Nutritional Composition, Therapeutic Potential, Environmental Impact, and Commercial Applications in Sustainable Industries.","authors":"Medisetti Manikishore, Sunny Rathee, Abhay Singh Chauhan, Umesh K Patil","doi":"10.2174/0113816128371677250806001232","DOIUrl":"https://doi.org/10.2174/0113816128371677250806001232","url":null,"abstract":"<p><p>Citrullus lanatus (watermelon) is a fruit with remarkable therapeutic potential, as each part of itrind, peel, flesh, and seeds contain bioactive compounds. Despite its wide range of benefits, the utilization of watermelon, particularly its rind, remains limited due to a lack of awareness and an underrated perspective. The rind, situated between the green outer peel and the red flesh, is light green in color and rich in bioactive compounds, minerals, and phytochemicals. These constituents are associated with various therapeutic properties, including antioxidant, antineoplastic, cardiovascular, and neuroprotective effects. In addition to its therapeutic applications, watermelon rind offers significant commercial value in the food, cosmetic, and pharmaceutical industries, as well as in industrial applications such as biofuel production and eco-friendly packaging. Its versatility makes watermelon rind an exciting area of research for uncovering new applications and enhancing existing ones. However, limitations in its usage and handling need to be addressed for its broader adoption. This review comprehensively discusses the global research conducted to date on the nutritional composition, therapeutic potential, environmental impact, and commercial applications of watermelon rind. Additionally, it highlights challenges and future directions for advancing the utilization of this promising resource.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nazia Nazam, Iftikhar Ahmad, Nasimudeen R Jabir, Torki A Zughaibi, Pallavi Agarwal, Ahdab Alsaieedi, Mohd Shahnawaz Khan, Shams Tabrez
{"title":"Deciphering Pharmacological Targets of Plumbagin in Cisplatin-resistant Ovarian Cancer Model using in vitro and in silico Approaches.","authors":"Nazia Nazam, Iftikhar Ahmad, Nasimudeen R Jabir, Torki A Zughaibi, Pallavi Agarwal, Ahdab Alsaieedi, Mohd Shahnawaz Khan, Shams Tabrez","doi":"10.2174/0113816128385767250808102022","DOIUrl":"https://doi.org/10.2174/0113816128385767250808102022","url":null,"abstract":"<p><strong>Introduction: </strong>Ovarian cancer (OC) is a malignancy of the female reproductive system for which cisplatin chemotherapy is one of the first-line treatments. Despite the initial response to chemotherapy, such patients eventually develop resistance, which poses a major obstacle to treatment, along with potential side effects. Phytochemicals function as chemosensitizers, offering novel therapies in OC patients by targeting drug resistance, and are perceived to be less toxic. Plumbagin has emerged as an anticancer compound, with some findings suggesting its anti-ovarian cancer activity. However, there is no study on the potential of plumbagin to target cisplatin resistance in non-high-grade OC. The current study aimed to determine the antitumor activity of plumbagin for cisplatin resistance in OC cells in vitro, and to identify its potential molecular target for therapeutic benefit using in silico studies.</p><p><strong>Methods: </strong>Plumbagin was used for in vitro cytotoxic effects on cisplatin-resistant (A2780-CR) and sensitive (A2780-CS) isogenic cell lines using a crystal violet cell viability assay. The binding of plumbagin to the nine selected molecular targets was estimated by molecular docking, and their binding energies were compared. The stabilities of the selected docked complexes were confirmed by molecular dynamics simulation (MDS) and molecular mechanics generalized born surface area (MM-GBSA) calculations, and conclusions were drawn to predict the inhibition potential of plumbagin to its best targets.</p><p><strong>Results: </strong>Plumbagin demonstrated the potential to kill A2780-CR cells, and, expectedly, the cell death effect on A2780-CS ovarian cancer cells demonstrated its anti-tumor activity in vitro. It was found to be noneffective in killing normal non-tumorigenic RPE cells, even at higher doses. Docking analysis suggested that it potentially inhibits ovarian cancer cells through various pharmacological targets with high affinity for binding to Chk1 (PDB ID=1ia8) and Aurora Kinase (PDB ID=5ORL). Molecular dynamic simulation data revealed strong and stable protein-ligand complex formation, which was measured in terms of root mean square deviation (RMSD), root mean square fluctuation (RMSF), and radius of gyration (Rg). On the other hand, the MM-GBSA study revealed that the binding free energy of the CT1019-1ia8 complex (-84.26 ± 2.99 Kcal/mol) and CT1019-5ORL (-67.04 ± 2.63 Kcal/mol) was better when compared to other complexes.</p><p><strong>Discussion: </strong>Plumbagin showed the anti-ovarian cancer benefits of plumbagin in cisplatin-resistant ovarian cells, and the potential pharmacological targets identified were Chk1 and Aurora kinase.</p><p><strong>Conclusion: </strong>Our study offers promising insights into plumbagin, particularly in combating cisplatin-resistant OC. However, further in vivo and mechanistic studies are required to validate plumbagin's potential as a therapeutic candidate for OC.</","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}